Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Hims & Hers Health, Inc. (NYSE:HIMS) shares fell over 6% in extended trading on August 10 after the telehealth company delivered another quarter of rapid growth alongside sharply weaker profitability. Revenue rose 38% year over year to $753.2 million, subscribers increased 19% to 2.89 million, and Monthly Revenue per Average Subscriber climbed 21% to $92. […]
Telehealth company Hims & Hers Health (NYSE:HIMS) announced better-than-expected revenue in Q2 CY2026, with sales up 38.2% year on year to $753.2 million. On top of that, next quarter’s revenue guidance ($890 million at the midpoint) was surprisingly good and 12.4% above what analysts were expecting. Its non-GAAP loss of $0.09 per share was significantly below analysts’ consensus estimates.
By Amina Niasse NEW YORK, Aug 12 (Reuters) - Hims & Hers Health plans to offer some legally available peptides in 2026, but investors and analysts who spoke to Reuters after the telehealth company's
Hims & Hers Health stock has pulled back recently yet is still up a little over 3x in five years, which leaves investors weighing that strong long term gain against a valuation profile that screens as neither clearly cheap nor clearly expensive. The share price has delivered about 341% over five years, so anyone looking at Hims & Hers Health today is assessing a company that has already created substantial returns over a medium term horizon. Growth expectations around its telehealth platform...
Morningstar’s $23 fair value implies a 25% downside, with a 'Very High Uncertainty' rating.
HIMS posts a wider-than-expected loss and weaker gross margin in second-quarter 2026 despite strong revenue growth and a raised full-year outlook.
Hims & Hers Health, Inc. reported second-quarter 2026 sales of US$753.21 million, up from US$544.83 million a year earlier, but moved from net income of US$42.51 million to a net loss of US$86.29 million, while also raising full-year 2026 revenue guidance to between US$3.10 billion and US$3.30 billion and issuing higher third-quarter revenue expectations. Alongside this growth outlook, the company is rolling out an AI-powered, personalized weight loss experience on the Hers app, supported by...
Hims & Hers Health (NYSE:HIMS) delivered mixed second-quarter results, with revenue beating Wall Street expectations while its quarterly loss came in wider than analysts had forecast as the company incurred restructuring charges tied to its shift toward branded GLP-1 weight-loss...
Hims & Hers Health raised its 2026 revenue outlook to between $3.1 billion and $3.3 billion from its earlier guidance between $2.8 billion and $3 billion.
Hims & Hers Health (HIMS) reported a mixed Q2, with upside in its US business from branded GLP-1 str
Hims & Hers raises its 2026 revenue outlook as AI boosts engagement, specialty care expands and Eucalyptus extends its international reach despite margin pressure.
Revenue beat expectations and guidance rose, but falling margins cloud the outlook
Revenue is still growing fast, but margins and free cash flow are moving in the wrong direction.
Telehealth company Hims & Hers Health (NYSE:HIMS) will be announcing earnings results this Monday after market hours. Here’s what to expect.
The telehealth company posted a net loss of $86.3 million in the second quarter while raising its full-year revenue outlook to $3.1–$3.3 billion
Aug 11 (Reuters) - Hims & Hers Health's shares fell nearly 7% in premarket trading on Tuesday, as concerns over shrinking profit margins overshadowed strong subscriber growth and a raised annual revenue forecast. The company posted second-quarter revenue on Monday that topped expectations and added more than 300,000 subscribers.
Stocks looked set to struggle for direction on Tuesday as investors worried about inflation, with hopes of Iran agreeing a deal to reopen the crucial Strait of Hormuz shipping route fading fast.
Strong subscriber growth and international expansion drive record performance, offset by margin pressures and FTC legal challenges.
Hims & Hers Health (NYSE:HIMS) reported second-quarter 2026 revenue of more than $753 million, up nearly 40% from a year earlier, as the telehealth company added 300,000 net new subscribers and ended the period with nearly 3 million subscribers globally. Chief Financial Officer Yemi Okupe said dome
Hims called Wegovy pill demand “staggering” and plans new testosterone and peptide treatments.
The telehealth company reported a second-quarter net loss of $86.3 million versus prior-year net income of $42.5 million.
Hims & Hers Health (HIMS) delivered earnings and revenue surprises of -42.86% and +9.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Health shares are down after the telehealth firm reduced the top end of its adjusted Ebitda forecast for the full year. Madison Muller reports on "Bloomberg The Close."
Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications.
Investing.com -- Hims & Hers Health reported a wider-than-expected second-quarter loss on Monday, sending its shares down 1.5%.
The telehealth platform said it now projects $3.1 billion to $3.3 billion in revenue for the year, up from a previous target for $2.8 billion to $3 billion.
Telehealth company Hims & Hers Health (NYSE:HIMS) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 38.2% year on year to $753.2 million. On top of that, next quarter’s revenue guidance ($890 million at the midpoint) was surprisingly good and 12.4% above what analysts were expecting. Its GAAP loss of $0.37 per share was significantly below analysts’ consensus estimates.
NEW YORK, Aug 10 (Reuters) - Hims & Hers Health on Monday posted second-quarter revenue above estimates and raised its annual revenue forecast, as the telehealth company benefited from an increase in
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
